Can I read 2021 - Discoveryresearch and Development History of The Dopamine D2 Receptor Partial Agonists, Aripiprazole and Brexpipra on EtoBox?

2021 - Discoveryresearch and Development History of The Dopamine D2 Receptor Partial Agonists, Aripiprazole and Brexpipra by owen is a document available to read on EtoBox.

What is 2021 - Discoveryresearch and Development History of The Dopamine D2 Receptor Partial Agonists, Aripiprazole and Brexpipra about?

Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify®). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europe, Japan, and many other countries for several indications including schizophrenia, acute mania, adjunctive treatment of major depressive disorder (MDD), irritability associated with autistic disorder.

Author

owen

Language

EN